HC Wainwright Reiterates “$48.00” Price Target for Uniqure (NASDAQ:QURE)

Share on StockTwits

Uniqure (NASDAQ:QURE) received a $48.00 target price from research analysts at HC Wainwright in a research note issued on Friday, October 19th. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 86.63% from the stock’s previous close.

QURE has been the subject of several other research reports. Zacks Investment Research downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research report on Wednesday, October 17th. BidaskClub downgraded shares of Uniqure from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Cantor Fitzgerald assumed coverage on shares of Uniqure in a research report on Thursday, July 26th. They issued an “overweight” rating and a $58.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Uniqure in a research report on Thursday, October 18th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research report on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $49.67.

NASDAQ QURE traded down $1.51 during trading hours on Friday, reaching $25.72. The company’s stock had a trading volume of 242,562 shares, compared to its average volume of 293,676. The company has a current ratio of 7.56, a quick ratio of 8.36 and a debt-to-equity ratio of 0.05. Uniqure has a 52 week low of $13.71 and a 52 week high of $43.23.

Uniqure (NASDAQ:QURE) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.03. The business had revenue of $3.15 million during the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. As a group, research analysts expect that Uniqure will post -2.48 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. OppenheimerFunds Inc. purchased a new position in Uniqure during the 2nd quarter valued at about $63,553,000. Swiss National Bank purchased a new position in shares of Uniqure during the second quarter worth about $1,550,000. BlackRock Inc. grew its holdings in shares of Uniqure by 6.7% during the second quarter. BlackRock Inc. now owns 464,426 shares of the biotechnology company’s stock worth $17,555,000 after purchasing an additional 29,299 shares in the last quarter. Macquarie Group Ltd. grew its holdings in shares of Uniqure by 1.5% during the second quarter. Macquarie Group Ltd. now owns 598,900 shares of the biotechnology company’s stock worth $22,639,000 after purchasing an additional 8,900 shares in the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in shares of Uniqure by 21.0% during the second quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock worth $22,869,000 after purchasing an additional 105,000 shares in the last quarter. 59.10% of the stock is owned by institutional investors and hedge funds.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Article: What Factors Can Affect Return on Equity?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.